The European Pharmaceutical Regulatory Authority, in particular the European Medicines Authority (EMA), has defended the use of the Coronavirus vaccine developed by the University of AstraZeneca / Oxford, despite growing concerns about the department. blood clots in some people who were injected with injectable drugs.
“The number of general thromboembolic events among vaccinated persons does not appear to be higher than what has been seen in the general population,” the EMA said in a statement released Tuesday. assessment of the World Health Organization (WHO), which said that there is no information about coagulation phenomena caused by vaccines.
Amsterdam-based company head Emer Cooke emphasized that “the benefits of the AstraZeneca vaccine in preventing COVID-19, with its associated risk of hospitalization and death, outweigh the risk of side effects. “.
Speaking at a press conference, the EMA’s CEO expressed her concerns about the suspension of vaccines, arguing that they could “have an effect on vaccine trust … but the mission Ours is to make sure the products we authorize are safe ”.
An extraordinary meeting has been scheduled on Thursday to review all the information gathered and make any necessary recommendations for further actions. The review is being carried out by the Pharmaceutical Alert Risk Assessment Committee (PRAC) of the EMA, which is responsible for assessing safety issues for medicinal products for humans.
Notice of EMA is given after several EU countries announced they suspended the use of the injection as a “precautionary measure” until the conclusion of their investigation of clot concerns.
At the beginning of Monday, Germany, France, Italy and Spain halted their jab deployments and Portugal, Luxembourg and Slovenia followed suit later in the day, while Latvia and Sweden continued on Tuesday morning. .